Nuvectis’ partner reports expanded glioma responses for experimental BRAF inhibitor
Nuvectis ($NVCT) reported expanded Phase 1b results for NXP200 from partner Haisco’s Chinese study in recurrent or progressive BRAF V600-mutated glioma. Tumor responses occurred in eight of twenty evaluable patients with high-grade disease and three of seven with low-grade disease. The groups included three and one complete responses, respectively, although one high-grade complete response remained preliminary. Median response duration in high-grade glioma was 6.97 months. This is indirect partn
0